
@DukeCancer Breast Medical Oncologist, via @MDAndersonNews Heme/Onc Fellowship, @OslerResidency, @HopkinsMedicine. Tweets are my own.
Durham, NC
Joined April 2019
- Tweets138
- Following224
- Followers238
- Likes307
Marija Sullivan, MD retweeted
👏👏👏Congratulations to Dr @LindaResar for her lifetime achievement of work in winning the 2026 Award 🥇 for Excellence in Translational Research at the 18th International Congress on MPNs in Brooklyn NY !! #MPNSM | @PedsHemeDoc @mpdrc @nsarellano9 @homesforhealers
Marija Sullivan, MD retweeted
Dr. Jennifer Plichta has been awarded a ⭐️ R01 grant ⭐️for her project addressing a lack of prognostic staging systems for patients with recurrent breast cancer. Congratulations, Dr. Plichta! 🤩🤩🤩 We cannot be more proud of her!!! @JenniferPlichta @DukeCancer @DukeSurgery
Marija Sullivan, MD retweeted
Real talk: is there a woman more generous, genius, or glamorous than Dr Mariana Chavez MacGregor? So excited for her time to help plan the @ASCO Annual Meeting. 🤩
Marija Sullivan, MD retweeted
Dr. Laura Burns Amin presented results at #ASCO26 showing pCR in triple-negative lobular breast cancer (TN-ILC) may lack the prognostic significance it has in triple-negative invasive ductal carcinoma (TN-IDC). #EndCancer
Marija Sullivan, MD retweeted
Feeling grateful this #ASCO26 for mentors who have shaped my career path: Drs. Chavez-MacGregor and Giordano, former co-fellows now junior faculty @inimfonjackson and @marijasullivan, and Dr. Lo, the first breast medical oncologist I worked with as a medical student.
An inspiring Gianni Bonadonna Breast Cancer Award lecture from Dr. Sharon Giordano at #ASCO26, honoring not only her contributions to breast cancer outcomes research, but also the career journey, challenges, and moments of meaning behind the work.
@UTMDAnderson
Marija Sullivan, MD retweeted
Two researchers will be honored with @ASCO’s 2026 Special Awards: Sharon Giordano for the Gianni Bonadonna Breast Cancer Award and Eduardo Vilar-Sanchez for the ASCO-American Cancer Society Cancer Prevention Award. spr.ly/6010B8X8u0 @shgiordano @evilarsan #ASCO26 #EndCancer
Marija Sullivan, MD retweeted
Replying to @SABCSSanAntonio
@SABCSSanAntonio Inimfon Jackson from MDACC highlights disparities in IO use and access in the US. Disparities/access is a key issue across the world - but still in the US. We need to work together for change @OncoAlert
Reunited with @MDAndersonNews Breast Medical Oncology colleagues at #SABCS25 ✨
Marija Sullivan, MD retweeted
Excellent presentation by @RosenbergerMd #phyllodes expert 🌟importance of standardized path reporting, her amazing work on genomic landscape, adjuvant therapies 👇🏼👇🏼👇🏼#SABCS25 @DukeSurgOnc
Marija Sullivan, MD retweeted
Replying to @RosenbergerMd
Excellent presentation by @RosenbergerMd #phyllodes expert 🌟importance of standardized path reporting, her amazing work on genomic landscape, adjuvant therapies 👇🏼👇🏼👇🏼#SABCS25 @DukeSurgOnc
Marija Sullivan, MD retweeted
lidERA trial shows significant improvement in IDFS and DRFI @SABCSSanAntonio !!
⭐️first adjuvant ET trial showing benefit of oral SERD over SOC ET
❗️of note did not allow for adj CDK4/6i ❓how will we incorporate that into practice?
❓Combination adj therapy? Do we need both?
Marija Sullivan, MD retweeted
Congratulations to the @MDAndersonNews trainees who received 2025 @ConquerCancerFd Young Investigator and Merit Awards for their contributions to cancer research! Extremely grateful for your hard work and commitment to our mission to #EndCancer. So well-deserved!
Marija Sullivan, MD retweeted
So thankful to @ConquerCancerFd for the 2025 @ASCO YIA! I am especially grateful to my amazing mentors and to @MDAndersonNews for their unwavering support and guidance. Congrats to my fellow awardees. Proud to be a part of this inspiring group! #makingcancerhistory
Congratulations to this year’s class of Conquer Cancer grant and award recipients! Are you one of them? Tell us in the comments! We can't wait to celebrate with you at #ASCO25. Full list of recipients: brnw.ch/21wSR0A
@ASCO
Marija Sullivan, MD retweeted
Very exciting!!! We need new drugs especially in mTNBC and especially post topo-1 ADCs as they move further up in our treatment paradigm
Particularly excited about the activity in #TNBC post topo-1 ADCs.
86% had seen savituzumab govitecan, 1/3 had seen T-DXd, 1/4 had seen both!
#ASCO25 #ADC #NewTargetNewPayload
Marija Sullivan, MD retweeted
Replying to @CYJiangMD
@CYJiangMD is doing some impressive work on MTAP loss in bladder cancer. Come check it out. @MDAndersonNews #ASCO25 #endcancer
Marija Sullivan, MD retweeted
Dr. Marija Sullivan shared real-world insights on Oncotype DX testing and chemotherapy use in early-stage HR+ breast cancer at #ASCO25. The data show variation in testing and treatment patterns by recurrence score, age, insurance type and other clinical factors. #EndCancer @marijasullivan
Marija Sullivan, MD retweeted
At #ASCO25, Dr. Inimfon Jackson, with mentor Dr. Mariana Chavez Mac Gregor, presented data on chemotherapy declination in early-stage HR+ breast cancer. Among patients with high Oncotype DX scores, 11% declined chemotherapy despite physician recommendation. This was associated with worse overall survival. #EndCancer @inimfonjackson
Marija Sullivan, MD retweeted
Huge congratulations to my friend and @MDAndersonNews co-fellow @marijasullivan on her impactful work looking at the real-world patterns of Oncotype testing & chemo use in early-stage HR+ breast cancer #ASCO25











































